These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

210 related items for PubMed ID: 20814332

  • 1. A randomized, 3-phase, 34-week, double-blind, long-term efficacy study of osmotic-release oral system-methylphenidate in adults with attention-deficit/hyperactivity disorder.
    Biederman J, Mick E, Surman C, Doyle R, Hammerness P, Kotarski M, Spencer T.
    J Clin Psychopharmacol; 2010 Oct; 30(5):549-53. PubMed ID: 20814332
    [Abstract] [Full Text] [Related]

  • 2. Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder.
    Wilens TE, McBurnett K, Bukstein O, McGough J, Greenhill L, Lerner M, Stein MA, Conners CK, Duby J, Newcorn J, Bailey CE, Kratochvil CJ, Coury D, Casat C, Denisco MJ, Halstead P, Bloom L, Zimmerman BA, Gu J, Cooper KM, Lynch JM.
    Arch Pediatr Adolesc Med; 2006 Jan; 160(1):82-90. PubMed ID: 16389216
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study.
    Adler LA, Zimmerman B, Starr HL, Silber S, Palumbo J, Orman C, Spencer T.
    J Clin Psychopharmacol; 2009 Jun; 29(3):239-47. PubMed ID: 19440077
    [Abstract] [Full Text] [Related]

  • 4. A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder.
    Biederman J, Mick E, Surman C, Doyle R, Hammerness P, Harpold T, Dunkel S, Dougherty M, Aleardi M, Spencer T.
    Biol Psychiatry; 2006 May 01; 59(9):829-35. PubMed ID: 16373066
    [Abstract] [Full Text] [Related]

  • 5. Are stimulants effective in the treatment of executive function deficits? Results from a randomized double blind study of OROS-methylphenidate in adults with ADHD.
    Biederman J, Mick E, Fried R, Wilner N, Spencer TJ, Faraone SV.
    Eur Neuropsychopharmacol; 2011 Jul 01; 21(7):508-15. PubMed ID: 21303732
    [Abstract] [Full Text] [Related]

  • 6. A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of osmotic-controlled release oral delivery system methylphenidate HCl in adults with attention-deficit/hyperactivity disorder in Japan.
    Takahashi N, Koh T, Tominaga Y, Saito Y, Kashimoto Y, Matsumura T.
    World J Biol Psychiatry; 2014 Aug 01; 15(6):488-98. PubMed ID: 24456065
    [Abstract] [Full Text] [Related]

  • 7. Single- and multiple-dose pharmacokinetics of methylphenidate administered as methylphenidate transdermal system or osmotic-release oral system methylphenidate to children and adolescents with attention deficit hyperactivity disorder.
    Pierce D, Katic A, Buckwalter M, Webster K.
    J Clin Psychopharmacol; 2010 Oct 01; 30(5):554-64. PubMed ID: 20814325
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of prolonged-release OROS methylphenidate in adults with attention deficit/hyperactivity disorder: a 13-week, randomized, double-blind, placebo-controlled, fixed-dose study.
    Casas M, Rösler M, Sandra Kooij JJ, Ginsberg Y, Ramos-Quiroga JA, Heger S, Berwaerts J, Dejonckheere J, van der Vorst E, Schäuble B.
    World J Biol Psychiatry; 2013 May 01; 14(4):268-81. PubMed ID: 22106853
    [Abstract] [Full Text] [Related]

  • 9. A randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder.
    Medori R, Ramos-Quiroga JA, Casas M, Kooij JJ, Niemelä A, Trott GE, Lee E, Buitelaar JK.
    Biol Psychiatry; 2008 May 15; 63(10):981-9. PubMed ID: 18206857
    [Abstract] [Full Text] [Related]

  • 10. Predictors of treatment outcome in adults with ADHD treated with OROS® methylphenidate.
    Buitelaar JK, Kooij JJ, Ramos-Quiroga JA, Dejonckheere J, Casas M, van Oene JC, Schäuble B, Trott GE.
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Mar 30; 35(2):554-60. PubMed ID: 21185347
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ, Wilens TE, Biederman J, Weisler RH, Read SC, Pratt R.
    Clin Ther; 2006 Feb 30; 28(2):266-79. PubMed ID: 16678648
    [Abstract] [Full Text] [Related]

  • 12. Does OROS-methylphenidate improve core symptoms and deficits in executive function? Results of an open-label trial in adults with attention deficit hyperactivity disorder.
    Fallu A, Richard C, Prinzo R, Binder C.
    Curr Med Res Opin; 2006 Dec 30; 22(12):2557-66. PubMed ID: 17166338
    [Abstract] [Full Text] [Related]

  • 13. A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention deficit-hyperactivity disorder.
    Steele M, Weiss M, Swanson J, Wang J, Prinzo RS, Binder CE.
    Can J Clin Pharmacol; 2006 Dec 30; 13(1):e50-62. PubMed ID: 16456216
    [Abstract] [Full Text] [Related]

  • 14. OROS-methylphenidate efficacy on specific executive functioning deficits in adults with ADHD: a randomized, placebo-controlled cross-over study.
    Bron TI, Bijlenga D, Boonstra AM, Breuk M, Pardoen WF, Beekman AT, Kooij JJ.
    Eur Neuropsychopharmacol; 2014 Apr 30; 24(4):519-28. PubMed ID: 24508533
    [Abstract] [Full Text] [Related]

  • 15. Prospective, naturalistic study of open-label OROS methylphenidate treatment in Chinese school-aged children with attention-deficit/hyperactivity disorder.
    Zheng Y, Wang YF, Qin J, Wang LW, Zou LP, Jin XM, Xu T, Wang Y, Qi YL, Gong ME, Yin QY, Mai JN, Jing J, Luo XY, Ma HW, Li HB, Xie L, Li Y, Kuang GF, Yi MJ, Wang F, Zhu XH, Yao YB.
    Chin Med J (Engl); 2011 Oct 30; 124(20):3269-74. PubMed ID: 22088519
    [Abstract] [Full Text] [Related]

  • 16. Relative benefits of stimulant therapy with OROS methylphenidate versus mixed amphetamine salts extended release in improving the driving performance of adolescent drivers with attention-deficit/hyperactivity disorder.
    Cox DJ, Merkel RL, Moore M, Thorndike F, Muller C, Kovatchev B.
    Pediatrics; 2006 Sep 30; 118(3):e704-10. PubMed ID: 16950962
    [Abstract] [Full Text] [Related]

  • 17. Better efficacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypes.
    Chou WJ, Chou MC, Tzang RF, Hsu YC, Gau SS, Chen SJ, Wu YY, Huang YF, Liang HY, Cheng H.
    Psychiatry Clin Neurosci; 2009 Apr 30; 63(2):167-75. PubMed ID: 19335386
    [Abstract] [Full Text] [Related]

  • 18. A double-blind, placebo-controlled trial of dexmethylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in children with attention-deficit/hyperactivity disorder.
    Wigal S, Swanson JM, Feifel D, Sangal RB, Elia J, Casat CD, Zeldis JB, Conners CK.
    J Am Acad Child Adolesc Psychiatry; 2004 Nov 30; 43(11):1406-14. PubMed ID: 15502600
    [Abstract] [Full Text] [Related]

  • 19. Twenty-four-week treatment with extended release methylphenidate improves emotional symptoms in adult ADHD.
    Rösler M, Retz W, Fischer R, Ose C, Alm B, Deckert J, Philipsen A, Herpertz S, Ammer R.
    World J Biol Psychiatry; 2010 Aug 30; 11(5):709-18. PubMed ID: 20353312
    [Abstract] [Full Text] [Related]

  • 20. Predictors of placebo response in adults with attention-deficit/hyperactivity disorder: data from 2 randomized trials of osmotic-release oral system methylphenidate.
    Buitelaar JK, Sobanski E, Stieglitz RD, Dejonckheere J, Waechter S, Schäuble B.
    J Clin Psychiatry; 2012 Aug 30; 73(8):1097-102. PubMed ID: 22780962
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.